Quantitation of leukemia clone-specific antigen gene rearrangements by a single-step PCR and fluorescence-based detection method.

Abstract:

:PCR-based detection of minimal residual disease (MRD) in children with precursor B cell acute lymphoblastic leukemia (pre-B ALL) by amplification of clone-specific antigen gene rearrangements has been labor-intensive. In this study we present a simpler, yet accurate, method to assess and quantitate MRD in pediatric pre-B ALL that utilizes these markers. From the sequence of the immunoglobulin heavy chain (IgH) and T cell receptor (TcR) gene rearrangements characterized at the time of diagnosis or relapse, primers were designed and tested in a clone-specific, single-round PCR assay, then analyzed by fluorescence staining of the PCR products. The most critical step involved an adherence to a new set of guidelines for the design of clone-specific primers. Application of this method to 54 IgH and 13 TcR (nine Vdelta2Ddelta3 and four Ddelta2-Ddelta3) gene rearrangements in 47 patients resulted in an intense band within the region of the predicted molecular weight, confirming the reproducibility of the assay. Quantitative applications of the approach were examined by performing a 10-replicate limiting dilution clone-specific PCR on six diagnostic samples and an asymptotic response model of the Von Krogh form was found to fit the data well. From this model, estimation of leukemic cells of remission bone marrow samples was achieved at a detection sensitivity of 2 x 10(-6). The method is demonstrated on 18 patients whose marrows were prospectively analyzed during therapy. We conclude this methodology is useful in the quick and accurate assessment of MRD in children with pre-B ALL, and could be applied to other DNA quantitation assays.

journal_name

Leukemia

journal_title

Leukemia

authors

Mayer SP,Giamelli J,Sandoval C,Roach AS,Fevzi Ozkaynak M,Tugal O,Rovera G,Jayabose S

doi

10.1038/sj.leu.2401530

subject

Has Abstract

pub_date

1999-11-01 00:00:00

pages

1843-52

issue

11

eissn

0887-6924

issn

1476-5551

journal_volume

13

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Secondary acute lymphoblastic leukaemia with 4:11 translocation following treatment for Hodgkin's disease: case report and review of the literature.

    abstract::It is apparent that treatment of Hodgkin's disease can be complicated by the development of secondary leukaemia. Most such leukaemias are of the non-lymphocytic type. We describe here a patient treated for Hodgkin's disease with chemo- and radiotherapy who developed secondary acute lymphoblastic leukaemia with a non-r...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Lennard A,Jackson GH,Carey PJ,Bown N,Middleton P,Proctor SJ

    更新日期:1991-07-01 00:00:00

  • Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions.

    abstract::To evaluate current detection methods for FIP1L1-PDGFRA in hypereosinophilic syndrome (HES), we developed a means to rapidly amplify genomic break points. We screened 202 cases and detected genomic junctions in all samples previously identified as RT-PCR positive (n=43). Genomic fusions were amplified by single step P...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.309

    authors: Score J,Walz C,Jovanovic JV,Jones AV,Waghorn K,Hidalgo-Curtis C,Lin F,Grimwade D,Grand F,Reiter A,Cross NC

    更新日期:2009-02-01 00:00:00

  • Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.

    abstract::Minimal residual disease (MRD) after allogeneic stem cell transplantation (SCT) for Ph+ acute lymphoblastic leukemia (ALL) is predictive of relapse. Imatinib administration subsequent to SCT may prevent relapse, but the role of scheduling and its impact on outcome are not known. In a prospective, randomized multicente...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/leu.2012.352

    authors: Pfeifer H,Wassmann B,Bethge W,Dengler J,Bornhäuser M,Stadler M,Beelen D,Vucinic V,Burmeister T,Stelljes M,Faul C,Dreger P,Kiani A,Schäfer-Eckart K,Schwerdtfeger R,Lange E,Kubuschok B,Horst HA,Gramatzki M,Brück P,S

    更新日期:2013-06-01 00:00:00

  • Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.

    abstract::The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase (PI3K), is known to play an important role in antiapoptotic signaling and has been implicated in the aggressiveness of a number of different human cancers including acute myeloid leukemia (AML). The progression of myelodysplastic s...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404057

    authors: Nyåkern M,Tazzari PL,Finelli C,Bosi C,Follo MY,Grafone T,Piccaluga PP,Martinelli G,Cocco L,Martelli AM

    更新日期:2006-02-01 00:00:00

  • Human bone marrow cytogenetics: growth factors stimulate metaphases for specific lineages.

    abstract::Fresh and/or frozen bone marrow cells from five healthy individuals and seven patients with myeloid leukemia were studied using growth factors and a cytogenetic technique which allows simultaneous analysis of karotype and cell lineage. Cell lineages were identified using monoclonal antibodies in an alkaline phosphatas...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Keinänen M,Bloomfield CD,Machnicki J,Griffin JD,de la Chapelle A

    更新日期:1989-06-01 00:00:00

  • In vivo inhibition of bovine leukemia virus (BLV) expression.

    abstract::Bovine leukemia virus-infected sheep were demonstrated to possess a plasma factor that specifically suppresses in vitro virus expression in lymphocyte cultures. This blocking activity is observed even after phytohemagglutinin (PHA) stimulation and is independent of cellular proliferation. Such a factor may play a crit...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Cornil I,Levy D

    更新日期:1989-02-01 00:00:00

  • IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.

    abstract::The added value of IKZF1 gene deletion (IKZF1(del)) as a stratifying criterion in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is still debated. We performed a comprehensive analysis of the impact of IKZF1(del) in a large cohort of children (n=1223) with BCR-ABL1-negative BCP-ALL treated in the EORTC-CLG tr...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/leu.2015.134

    authors: Clappier E,Grardel N,Bakkus M,Rapion J,De Moerloose B,Kastner P,Caye A,Vivent J,Costa V,Ferster A,Lutz P,Mazingue F,Millot F,Plantaz D,Plat G,Plouvier E,Poirée M,Sirvent N,Uyttebroeck A,Yakouben K,Girard S,Dastu

    更新日期:2015-11-01 00:00:00

  • Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis.

    abstract::The AML1 (RUNX1)-MTG8 (ETO) fusion transcription factor generated by the t(8;21) translocation is believed to deregulate the expression of genes that are crucial for normal differentiation and proliferation of hematopoietic progenitors, resulting in acute myelogenous leukemia. To elucidate the role of AML1-MTG8 in leu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402465

    authors: Shimada H,Ichikawa H,Ohki M

    更新日期:2002-05-01 00:00:00

  • Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital.

    abstract::We present the long-term results of three consecutive clinical trials (Total Therapy studies 11, 12 and 13A) conducted for children with newly diagnosed acute lymphoblastic leukemia (ALL) between 1984 and 1994. In study 11 (1984-1988), the overall event-free survival rates (+/-1 s.e.) were 71.8 +/- 2.4% and 69.3 +/- 2...

    journal_title:Leukemia

    pub_type: 杂志文章,meta分析

    doi:10.1038/sj.leu.2401938

    authors: Pui CH,Boyett JM,Rivera GK,Hancock ML,Sandlund JT,Ribeiro RC,Rubnitz JE,Behm FG,Raimondi SC,Gajjar A,Razzouk B,Campana D,Kun LE,Relling MV,Evans WE

    更新日期:2000-12-01 00:00:00

  • Clinical significance of beta 2-microglobulin in serum of adult T cell leukemia.

    abstract::To clarify the clinical and biological significance of beta 2-microglobulin (beta 2-M) in serum of adult T cell leukemia (ATL) associated with human lymphotropic virus type-I (HTLV-I), beta 2-M was measured in 52 patients with ATL (acute ATL, 35 patients; lymphoma ATL, two patients; chronic ATL, 12 patients; smolderin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Sadamori N,Mine M,Hakariya S,Ichiba M,Kawachi T,Itoyama T,Nakamura H,Tomonaga M,Hayashi K

    更新日期:1995-04-01 00:00:00

  • The WNT receptor ROR2 drives the interaction of multiple myeloma cells with the microenvironment through AKT activation.

    abstract::Multiple myeloma is the second most frequent hematological cancer after lymphoma and remains an incurable disease. The pervasive support provided by the bone marrow microenvironment to myeloma cells is crucial for their survival. Here, an unbiased assessment of receptor tyrosine kinases overexpressed in myeloma identi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0486-9

    authors: Frenquelli M,Caridi N,Antonini E,Storti F,Viganò V,Gaviraghi M,Occhionorelli M,Bianchessi S,Bongiovanni L,Spinelli A,Marcatti M,Belloni D,Ferrero E,Karki S,Brambilla P,Martinelli-Boneschi F,Colla S,Ponzoni M,DePinho R

    更新日期:2020-01-01 00:00:00

  • Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia.

    abstract::Heterozygous and homozygous deletions of chromosome 13q14.3 are found in 50% of patients with B cell CLL, suggesting the presence of one or more tumour suppressor genes within the deleted region. To identify candidate genes from the region, we constructed a map of 13q14.3 using a combination of genomic and cDNA librar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402551

    authors: Rowntree C,Duke V,Panayiotidis P,Kotsi P,Palmisano GL,Hoffbrand AV,Foroni L

    更新日期:2002-07-01 00:00:00

  • Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa.

    abstract::We assessed clinical results in 145 patients with chronic myeloid leukaemia in chronic phase who satisfied criteria for interferon-alpha failure and were thus eligible for treatment with imatinib at the Hammersmith Hospital. We used univariate and multivariate analyses to develop a risk score based on features defined...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402996

    authors: Marin D,Marktel S,Bua M,Szydlo RM,Franceschino A,Nathan I,Foot N,Crawley C,Na Nakorn T,Olavarria E,Lennard A,Neylon A,O'Brien SG,Goldman JM,Apperley JF

    更新日期:2003-08-01 00:00:00

  • Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome.

    abstract::Mutations of the GATA1 gene on chromosome X have been found in almost all cases of transient myeloproliferative disorder and acute megakaryoblastic leukemia (AMKL) accompanying Down syndrome (DS). Although most GATA1 mutations lead to the expression of GATA1s lacking the N-terminal activation domain, we recently found...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404223

    authors: Xu G,Kanezaki R,Toki T,Watanabe S,Takahashi Y,Terui K,Kitabayashi I,Ito E

    更新日期:2006-06-01 00:00:00

  • Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

    abstract::Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a ...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2016.299

    authors: Schlenk RF,Stegelmann F,Reiter A,Jost E,Gattermann N,Hebart H,Waller C,Hochhaus A,Platzbecker U,Schafhausen P,Blau IW,Verbeek W,Heidel FH,Werner M,Kreipe H,Teleanu V,Benner A,Döhner H,Grießhammer M,Döhner K

    更新日期:2017-04-01 00:00:00

  • Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.

    abstract::Current MRD studies in T-cell acute lymphoblastic leukemia (T-ALL) mainly use T-cell receptor gamma, delta and SIL-TAL1 gene rearrangements as MRD-PCR targets. However, low frequency or limited diversity of these markers restricts the number of evaluable patients, particularly because two markers are recommended for M...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403263

    authors: Brüggemann M,van der Velden VH,Raff T,Droese J,Ritgen M,Pott C,Wijkhuijs AJ,Gökbuget N,Hoelzer D,van Wering ER,van Dongen JJ,Kneba M

    更新日期:2004-04-01 00:00:00

  • DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells.

    abstract::The FMS-like tyrosine kinase-3 (FLT3) gene is the most commonly mutated gene in acute myeloid leukemia (AML), and patients carrying internal tandem duplication (ITD) mutations have a poor prognosis. Long-term inhibition of FLT3 activity in these patients has been elusive. To provide a more complete understanding of FL...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.284

    authors: Wu M,Hamaker M,Li L,Small D,Duffield AS

    更新日期:2017-03-01 00:00:00

  • The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes.

    abstract::The Wilms' tumor gene, WT1, is a tumor marker for leukemic blast cells. The WT1 expression levels were examined for 57 patients with myelodysplastic syndromes (MDS) (refractory anemia (RA), 35; RA with excess of blasts (RAEB) 14; RAEB in transformation (RAEB-t), six; and MDS with fibrosis, two) and 12 patients with ac...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401341

    authors: Tamaki H,Ogawa H,Ohyashiki K,Ohyashiki JH,Iwama H,Inoue K,Soma T,Oka Y,Tatekawa T,Oji Y,Tsuboi A,Kim EH,Kawakami M,Fuchigami K,Tomonaga M,Toyama K,Aozasa K,Kishimoto T,Sugiyama H

    更新日期:1999-03-01 00:00:00

  • The novel immunosuppressive enzyme IL4I1 is expressed by neoplastic cells of several B-cell lymphomas and by tumor-associated macrophages.

    abstract::We previously reported a strong IL4I1 gene expression in primary mediastinal B-cell lymphoma (PMBL) and recently identified the protein as a secreted L-phenylalanine oxidase, physiologically expressed by myeloid cells, which inhibits T-cell proliferation in vitro. Here, we analyzed the pattern of IL4I1 protein express...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.380

    authors: Carbonnelle-Puscian A,Copie-Bergman C,Baia M,Martin-Garcia N,Allory Y,Haioun C,Crémades A,Abd-Alsamad I,Farcet JP,Gaulard P,Castellano F,Molinier-Frenkel V

    更新日期:2009-05-01 00:00:00

  • The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia.

    abstract::The B-cell receptor (BCR) and its immature form, the precursor-BCR (pre-BCR), have a central role in the control of B-cell development, which is dependent on a sequence of cell-fate decisions at specific antigen-independent checkpoints. Pre-BCR expression provides the first checkpoint, which controls differentiation o...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2015.113

    authors: Eswaran J,Sinclair P,Heidenreich O,Irving J,Russell LJ,Hall A,Calado DP,Harrison CJ,Vormoor J

    更新日期:2015-08-01 00:00:00

  • Acute lymphoblastic leukemia with a hypodiploid karyotype with less than 40 chromosomes: the basis for division into two subgroups.

    abstract::This paper describes seven patients with ALL and a hypodiploid karyotype with less than 40 chromosomes. A consideration of these and 15 previously published cases indicates that they may be divided into two groups depending on chromosome number, i.e., less than 30 and 30-39. The less than 30 group are younger and pred...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Callen DF,Raphael K,Michael PM,Garson OM

    更新日期:1989-10-01 00:00:00

  • BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.

    abstract::Myeloproliferative neoplasms with myelofibrosis (MPN-MF) demonstrate constitutive activation of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling that responds to treatment with the JAK1 and 2 kinase inhibitor (JAKi) ruxolitinib. However, MPN-MF often progresses (~20%) to secondary acu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.260

    authors: Saenz DT,Fiskus W,Manshouri T,Rajapakshe K,Krieger S,Sun B,Mill CP,DiNardo C,Pemmaraju N,Kadia T,Parmar S,Sharma S,Coarfa C,Qiu P,Verstovsek S,Bhalla KN

    更新日期:2017-03-01 00:00:00

  • Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.

    abstract::Mitoxantrone is a synthetic aminoanthraquinone we have previously reported to be effective for patients with acute leukemia in relapse. We presently report the results of a trial of mitoxantrone in combination with cytosine arabinoside (ara-C) in patients with refractory or relapsed acute myelocytic leukemia (AML). Fo...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Paciucci PA,Dutcher JP,Cuttner J,Strauman JJ,Wiernik PH,Holland JF

    更新日期:1987-07-01 00:00:00

  • Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive onset type: results of a prospective study.

    abstract::Chronic graft-versus-host disease (GVHD) remains a serious complication after allogeneic hematopoietic stem cell transplantation (HCT). In 2005 the National Institutes of Health (NIH) established new criteria for chronic GVHD based on retrospective data and expert recommendations. We prospectively evaluated the incide...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.257

    authors: Kuzmina Z,Eder S,Böhm A,Pernicka E,Vormittag L,Kalhs P,Petkov V,Stary G,Nepp J,Knobler R,Just U,Krenn K,Worel N,Greinix HT

    更新日期:2012-04-01 00:00:00

  • Suppression of G-CSF-mediated Stat signalling by IL-3.

    abstract::G-CSF-induced myeloid differentiation of 32Dcl3 murine myeloblast cells is antagonized by concurrent exposure to interleukin-3 (IL-3) or by oncogenic transformation of 32Dcl3 by src- or abl-oncogenes which render the cells IL-3-independent. Recent reports have linked G-CSF-mediated differentiation to the ability of G-...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401253

    authors: Steinman RA,Iro A

    更新日期:1999-01-01 00:00:00

  • Detection of additional JH/BCL2 translocations in follicular lymphoma.

    abstract::In vitro enzymatic amplification and direct sequencing were used to detect and characterize t(14;18) recombination junctions in peripheral blood and bone marrow mononuclear cell preparations from patients with follicular lymphoma in remission. Samples from 24/44 patients were found to be positive for translocations in...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Price CG,Tuszynski A,Watt SM,Murdoch SJ,Lister TA,Young BD

    更新日期:1991-07-01 00:00:00

  • Effects of the farnesyl transferase inhibitor R115777 on normal and leukemic hematopoiesis.

    abstract::Patients with acute myelogenous leukemia or myelodysplastic syndrome may respond to farnesyl transferase inhibitors (FTIs) with partial or complete response rates noted in about 30% of such patients. FTIs prevent the attachment of a lipid farnesyl moiety to dependent proteins prior to their insertion into the plasma m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403063

    authors: Liesveld JL,Lancet JE,Rosell KE,Menon A,Lu C,McNair C,Abboud CN,Rosenblatt JD

    更新日期:2003-09-01 00:00:00

  • Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma.

    abstract::This analysis assessed the effect of lenalidomide on progression-free survival (PFS). Patients with relapsed or refractory multiple myeloma (RRMM) who received lenalidomide plus dexamethasone in the MM-009 and MM-010 trials were pooled and those who had not progressed and were still receiving lenalidomide at 12 months...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.126

    authors: Dimopoulos MA,Hussein M,Swern AS,Weber D

    更新日期:2011-10-01 00:00:00

  • Results of the randomized phase IIB ADMIRE trial of FCR with or without mitoxantrone in previously untreated CLL.

    abstract::ADMIRE was a multicenter, randomized-controlled, open, phase IIB superiority trial in previously untreated chronic lymphocytic leukemia. Conventional front-line therapy in fit patients is fludarabine, cyclophosphamide and rituximab (FCR). Initial evidence from non-randomized phase II trials suggested that the addition...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1038/leu.2017.65

    authors: Munir T,Howard DR,McParland L,Pocock C,Rawstron AC,Hockaday A,Varghese A,Hamblin M,Bloor A,Pettitt A,Fegan C,Blundell J,Gribben JG,Phillips D,Hillmen P

    更新日期:2017-10-01 00:00:00

  • The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells.

    abstract::The three DNA methyltransferase (DNMT)-inhibiting cytosine nucleoside analogues, azacitidine, decitabine and zebularine, which are currently studied as nonintensive therapy for myelodysplastic syndromes and acute myeloid leukemia (AML), differ in structure and metabolism, suggesting that they may have differential mol...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.397

    authors: Flotho C,Claus R,Batz C,Schneider M,Sandrock I,Ihde S,Plass C,Niemeyer CM,Lübbert M

    更新日期:2009-06-01 00:00:00